PharmaEssentia announced yesterday that it has applied for market approval in Vietnam for its new drug, BESREMi (Ropeginterferon alfa-2b, also known as Ropeg or P1101), for the treatment of Polycythemia Vera (PV), marking its expansion into the Southeast Asian market.
Read more